NRG1 and Charcot-Marie-Tooth disease: Novel therapies, including gene therapy and targeted pharmaceuticals such as NRG-1 axis inhibitors and modulators of unfold protein response (UPR) and histone deacetylase (HDAC) enzyme family, are currently in development and promise to provide more precise treatment for CMT patients in the near future (Stavrou and Kleopa, 2023; Hertzog and Jacob, 2023; Beloribi-Djefaflia and Attarian, 2023).